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Polymorphism of stress-related genes is a key factor determining difference in the stress reactivity and
resistance among humans. Glucocorticoid receptors are important actors of stress responses. This review is
focused on the molecular biology and clinical implications of glucocorticoid receptor gene polymorphism.
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The diseases of civilization (arterial hypertension,
atherosclerosis, sugar diabetes, immunodeficiency,
autoimmune pathology, bipolar disorders and depre-
ssion) are of significant economic and humanitarian
damage to modern humankind. They are based on the
systemic down-regulation, occurring as a response to
the allostatic load, distress and disadaptation. Gluco-
corticoid hormones as stress effectors and agents of the
adaptation to stress take instant part in the regulation of
metabolism, homeostasis, immune reactions, end-
ocrine state and psychiatric processes, which influ-
ences the mood, memory, and general psychological
activity. Among genes-stress regulators, the genes of
glucocorticoid receptors should be paid special atten-
tion. The current review presents the analysis of the
genetics and molecular biology of the receptors of glu-
cocorticoid hormones (NR3C1), the spectrum of acti-
vation effects which includes the range from epigene-
tic modifications of the genome to the impact on psy-
chiatric processes.
Gene structure and expression regulation. The
glucocorticoid hormone receptor gene NR3C1 (nuclear
receptor subfamily 3, group C, class 1) is present in the
human genome in the only copy, located in the locus
5q31.3 (long arm of chromosome 5, site 3, band 1, sub-
band 3). The length of the gene is 157581 base pairs, it
contains nine exons, coding for the sequences of 777
aminoacid residues [2]. The gene structure is presented
in Fig. 1 and 2.
The expression of NR3C1 gene is under the control
of several alternative first exons (according to different
data, from seven to nine), preceding CpG-rich sequence
(promotor region) [3, 4]. Seven tissue-specific pro-
motors, promoting different mechanisms of genetic
control over the gene expression in organs and tissues,
are localized in introns between these alternative exons.
The methylation of alternative exons and promotors is
the epigenetic mechanism of the regulation of gene
activity [4]. The activity of different promotors is likely
to have impact on the choice of a specific mechanism of
splicing, leading to the formation of some isoforms of
receptors. The genetic polymorphism of the regulatory
sites is known for its association with the development
of depressive disorders [5].
Splicing and translation. Receptor isoforms. The
formation of eight splice-variants, coding for four main
isoforms of the receptor – GR-, GR-, GR-, as well
as little-studied isoform GR-P is possible after the
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alternative splicing of pro-mRNA, read from the
sequence ofNR3C1 gene (Table 1). Besides, the shift of
the reading frame in the process of the initiation of
translation leads to a number of additional isoforms of
the receptor GR- (GR-A, GR-B, GR-C and
GR-D; Table 2). This mechanism of the alternative
initiation of translation is typical for the synthesis of
protooncogenes, the transcription regulators, kinases
and growth factors in eukaryotes [7]; it allows in-
creasing the number of protein products of the same
gene, thus enlarging the range of its physiological
functions and the number of tissue-specific variants of
the response [6].
The receptor isoforms are remarkable for C-termi-
nal site which influences the mechanisms of cytoplasmic-
nuclear traffic and the activation of target genes [6].
The most wide-spread form of the receptor is GR- [6],
the aminoacid sequence of which is presented in Fig. 1.
-Isoform is presented by a number of shorter subiso-
forms with some absent aminoacids at C-terminal end
(Table 2) which does not influence the binding to the
hormone, but modifies the processes of translocation of
the activated receptors into the nucleus [6].
The main distinction of the less prevailing variant,
GR-, the level of expression of which is about 1 % of
GR- one [8], is the absence of specific glucocor-
ticoid-binding domain [9]. -isoform is predominantly
localized in the nucleus and is likely to serve as a do-
minantly negative regulator of GR- and MR, it is also
capable of competing with the latter for the sites of pro-
motors as well as forming heterodimers [9, 8]. Thus,
lower level of sensitivity of neutrophils to glucocor-
ticoid-mediated apoptosis, compared to T-lympho-
cytes, is likely to be conditioned by the increased ex-
pression of GR- in these cells. At the same time some
authors doubt the capability of GR- to inhibit the
effects of GR- in the physiological and pathological
conditions, as due to the low level of GR- basic
expression, at least 500-fold increase in its synthesis is
required to obtain a significant effect [8]. It was estab-
lished that GR- inhibits only the transactivational
effects of GR-, not affecting the induced trans-
repression [8]. In addition, the effect of GR- on more
high-affine MR is also possible in the physiological
conditions [8]. It should be noted that the isoform GR-
is not observed in rats as they do not have the cor-
responding site of the active splicing in NR3C1 gene
[11]. The physiological significance of other isoforms
of the receptor, in particular, GR- and GR-P, is yet to
be studied in detail.
The isoform GR- was described by Rivers et al.
[12] in 1999. It contains an additional arginine in the
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structure of DNA-binding domain, occurring as a result
of alternative splicing of the intron between the 3rd and
4th exons. This modification is known to induce the re-
duction in the transcriptional activity of the receptor by
48% [13]. GR- is highly expressed in different tissues,
its share is in the range of 3.8–8.7 % in the total
population of GR receptors [12].
Receptor structure. The receptor consists of four
domains, three of which are presented by highly con-
servative sequences, present in other proteins (Table 3,
Fig. 3). The effect of GR is achieved via dimers, which
may exist in the form of homo- and heterodimers with
MR. Homo- and heterodimers induce different sub-
groups of genes, providing fine regulation depending
on changing levels of hormones in stress conditions
[14, 15]. In this respect high significance is attributed to
the fact that the character and magnitude of GR/MR-
mediated responses is determined not only by binding
receptors to ligands, but also by the presence of nonste-
roid coregulators, coactivators and corepressors [15].
The dimer configuration of a GR molecule differs from
that of the receptors of other steroid hormones and
contains an additional intermolecular -layer [16].
Receptor activation. Under basic cellular condi-
tions the receptor exists in the composition of a multi-
protein complex with one GR molecule and heat shock
proteins – two hsp90 molecules, one hsp70, one hsp56
and immunomodulin [8].
The hormone binding to the receptor leads to a
number of events, including the dissociation of heat
shock proteins, immunomodulin and phosphorylation
of GR, inducing the transportation of the
Identifier in the catalog
NCBI RefSeq
Characteristics Resulting protein Reference
NM_000176.2
Main transcript, coding the most common
receptor isoform
GR- isoforms, obtained after alternative variants of
mRNA translation initiation:
GR-A, GR-B, GR-C, GR-D and their subtypes
[6]
NM_001204258.1
NM_001204259.1
NM_001204260.1
NM_001204261.1
NM_001204262.1
NM_001204263.1
NM_001204264.1
NM_001018074.1 Variants with alternative 5’-non-coding
sequences
NM_001018075.1
NM_001018076.1
NM_001018077.1
NM_001020825.1
Formed due to alternative site of
splice-acceptors in 3’-terminal exon
GR- [9]
NM_001024094.1
Formed due to alternative splicing in the
site of one of the encoding exons
GR- [12]
NM_001204265.1 Variant without two exons at 3’-end GR-P [40, 41]
Table1
Human gene NR3C1 mRNA spilce variant
hormonereceptor complex in the nucleus [8]. The
half-life of the hormone-receptor complex for GR is 5
min (compared to 45 min for MR) [14]; KD dissociation
constant is 0.5 nM [8].
The level of receptor-activating glucocorticoid
hormones in blood is susceptible to pulse fluctuations
in the course of 24 hours. The average duration of one
secretion pulse for rats is approximately one hour. In
the evening the secretion peaks are more frequent, they
follow each other almost without any intervals and have
high amplitude; in the morning their amplitude is
decreased and they are divided by intervals of half an
hour or an hour [14, 17]. In the blood the glucocorti-
coids interact with corticosteroid-binding proteins
(CBP) [8]; their penetration via hematoencephalic
barrier is regulated by P-glycoprotein mdr1A (multiple
drug resistance) [18].
The peak concentrations of glucocorticoids in
blood induce the activation and translocation of GR
molecules into the nucleus as early as after 30 min (in
the basic conditions GR receptors in the nucleus are
practically not present) [14, 19]. Then their level
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Isoform Structure Localization and function
GR- (-A,
GR-A)
Main receptor isoform, containing DNA- and
hormone-binding domains
Located in the cytoplasm; is transported into the nucleus after
ligand-binding, where it operates. Isoforms differ in the
mechanisms of transportation into the nucleus [6]
GR-B Terminated at codon 571–573 Short receptor isoforms, different in the mechanisms of
transportation into the nucleus [6]
GR-C1 Terminated at codon 748–750
GR-C2 Terminated at codon 760–762
GR-C3 Terminated at codon 784–786
GR-D1 Terminated at codon 1438–1440
GR-D2 Terminated at codon 1483-1485
GR-D3 Terminated at codon 1498-1500
GR-
Shorter isoform, compared to GR- ,with prominent
C-terminal part, non-containing the hormone-binding
domain [9]. Not observed in rats [11].
Predominantly localized in the nucleus, a dominantly-negative
regulator of GR- activity [9].
GR- DNA-binding domain contains the additional amino
acid (arginine)
Lower affinity to GRE compared to GR- [12]
GR-P Shorter C-terminal area, not observed in other
isoforms
Unknown function. Highly expressed in glucocorticoid-resistant
cell lines, may serve as a modulator of susceptibility to
glucocorticoids [40, 41]
Table2
Human GR receptor isoforms (gene NR3C1)
Localization Domain Function
1–420 Transactivational Interaction with transcription factors
419–486 DNA-binding by “zinc fingers” type Interaction with GRE-sequence of DNA and modulation
of transcription initiation frequency
487–527 Hinged Molecular structure motility
528–777 Ligand-binding Hormone-binding, translocation into the nucleus
Table3
GR-A proteins' domains
diminishes to the initial values rather fast (in the course
of 90 min) [14, 19]. Therefore, the total duration of the
activation cycle of receptors, their translocation and
elimination from the nucleus is 120 min. The elimi-
nation of receptors from the nucleus occurs due to their
proteasome degradation in the nucleus; it is blocked by
the inhibitors of 26S-subunit of the proteasome [14].
The cytoplasmic concentration of receptors in the
course of this cycle does not decrease considerably
which testifies to only a small amount of receptors,
passing in each recruiting cycle [14].
Post-translational modification. Currently 14 dif-
ferent variants of post-translational modification are
described for human GR molecule, including phospho-
rylation, sumoylation and ubiquitination (Table 4). The
phosphorylation and dephosphorylation of GR are of
considerable impact on the function of the receptor, its
intracellular traffic and affinity to ligands [20]. In a free
state the receptor is phosphorylated (sites Tre171 and
Ser246 in GR of rats [21]), however, the binding of the
hormone (not the antagonists) leads to its further
phosphorylation, which is likely required for the phy-
siological activity [22]. This phosphorylation seems to
occur in sites Ser 203 and Ser211 with the participation
of cyclin-dependent kinases [20, 22]. These phospho-
rylation sites are related to the regulation of the traffic
of the activated receptor into various cellular
compartments: GR-Ser211P is found in the nucleus,
while GRSer203-P and twice phosphorylated GR-Ser
203/Ser211-P are present only in the cytosol [22]. The
phosphorylation of Ser226 site with the involvement of
JNK and MAPK leads to the accelerated withdrawal of
the receptor from the nucleus, inhibiting the tran-
scription of glucocorticoid-dependent genes [23, 21].
The replacement of serine by alanine (Ser266A1a) in
this locus induces the loss of sensitivity of GR receptor
to the effect of JNK [23]. The activation of JNK occurs
with the participation of cytokines, lipopolysaccharides
and osmotic stimuli [23] and the phosphorylation by
Ser226 residue may be the mechanism of contra-
regulation of the systemic immune and stress response.
Besides the phosphorylation, GR protein is affected
by the recently discovered process of sumoylation,
conjugated with specific small ubiquitin-related mo-
difier (SUMO-1) [24]. The process is catalyzed by
E3-ligases, which are different from the ligases,
participating in the ubiquitination. The sumoylation
modifies the traffic and the activity of a number of
proteins. GRs may be sumoylated in three loci, related
to the transactivational domain (Lys277 and Lys293)
and the ligand-binding domain in the C-terminal region
(Lys703) which leads to the modification of the
transcriptional activity of the receptor, and the obser-
ved effect is promotor-dependent [24]. The sites of the
transactivational domain are more susceptible to this
type of modification compared to those of the ligand-
binding domain. The glucocorticoid hormones are li-
kely to stimulate the sumoylation of the receptor via its
translocation into the nucleus with the corresponding
E3-ligase (Ubc9) [24].
The glucocorticoid receptor may function in two
modes: as a transcription factor, binding to the glucoco-
rticoid-responsive elements of DNA (GRE) and as a
regulator of the activity of other transcriptional factors.
In 2009 it was established that different GR-binding
nucleotide sequences of DNA serve as cofactors in the
activity of the receptor, specifically and differentially
changing its conformation and thus affecting the
expression of some genes [25].
Receptor degradation. Similar to the majority of
other nuclear receptors, GR is a substrate of the ubiqui-
tin-dependent proteasome degradation [14, 26, 27].
CHIP complexes [26] and the protein Mdm2 (E3-li-
gase) participate in the processes of the proteasome de-
gradation of receptors [28].
The recruiting of various subunits of the pro-
teasome and E3-ligases into the promotor region during
the activation of the steroid hormone receptors is a
required condition for their effect, and the blockade of
proteasome proteolysis may cause the association of
the receptors and chromatin [26]. On the other hand, the
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Fig. 3 DNA-binding domain of the glucocorticoid receptor
inhibition of proteasome degradation of proteins leads
to the enhanced transcriptional activity in tissues which
may be related to the impaired degradation and per-
sistent activity of the transcription factors in the
nucleus. Another mechanism of the participation of
proteasome degradation in the regulation of the activity
of the glucocorticoid receptors is the stimulating effect
of various agents, estrogens, in particular, on the ex-
pression of the specific E3-ligase Mdm2, inducing the
decrease in GR activity [28]. Therefore, the activity of
the proteasome is a key element in the dynamic regu-
lation of the activity of steroid hormones.
Genetic polymorphism of NR3C1 gene. The
polymorphism of genes, participating in the impleme-
ntation of the stress response, is likely to play the key
role, determining the discrepancies between the stress-
responsiveness and resistance in the human population
[1]. According to the data of the National Institutes of
Health (USA) there are currently 2,571 known poly-
morphisms of human NR3C1 gene of the single nuc-
leotide polymorphism type (SNP, Fig. 4); among these
polymorphisms, the incidence degree of the minor
allele for 167 and 127 of them is over 10% and 1%,
respectively. We have discovered 42 missence-mu-
tations among all SNPs, inducing the substitution of
some amino acids in the structure of different isoforms
of GR receptors. In addition to SNP, there are scientific
literature data on the familial mutation of NR3C1 gene
with the deletion of four nucleotides, related to the in-
tron and exon sites and leading to the termination of the
expression of the damaged gene [29].
Missence polymorphisms. There are data on 42
missence SNPs in each of four domains of the proteins
(Table 5). This Table demonstrates that the highest
clinical significance is attributed to the polymorphisms,
related to the transactivational and ligand-binding
domains. The main impairments of the receptor func-
tion for these polymorphisms are as follows:
1) retardation of the activated receptor traslocation
into the nucleus (proven for rs104893912, rs121
909727 and rs104893908);
2) decreased affinity to the hormone (proven for
rs121909727, rs104893908) or co-activators (proven
for rs104893912, rs121909727);
3) the receptor instability (proven for
rs104893908);
4) decrease in the transactivational activity (proven
for rs104893912, rs121909727 and rs104893914;
assumed for rs148967394).
Among the polymorphisms given in Table 5,
rs121909726, rs56149945, rs104893909,
rs104893910, rs104893911, rs104893912,
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¹ Position Aminoacid Modification Kinase Significance Reference
1 8 Threonine Phosphorylation – – –
2, 4 45, 134 Serine Phosphorylation – – –
3, 5 133, 141 Serine Phosphorylation – – [20, 42]
7, 8 203, 211 Serine Phosphorylation Cdk Activates the receptor after
hormone-binding
[22]
9 226 Serine Phosphorylation ERK2, MAPK-8,
JNK
Decreases receptor activity [21, 23]
10 234, 267 Serine Phosphorylation – – –
11 277, 293 Lysine Sumoylation Ubc9 (E3-ëèãàçà) – [24]
12 419 Lysine
Ubiquitination in
DNA-binding domain
CHIP, Mdm2
(E3-ëèãàçà)
Possible PEST-marker of degradation [26–28]
13 508 Serine Phosphorylation of the
hinged domain
DNA-dependent
protein kinase
Effects the transcriptional activity
[43]
14 703 Lysine Sumoylation Ubc9 (E3-ëèãàçà) – [24]
Table4
Postranslational modification GR-A sites
rs104893913, rs104893914, rs121909727 have been
described in humans. All of them are the consequences
of missence mutations, impairing the protein structure,
and each of them induces the development of gene-
ralized familial forms of the glucocorticoid resistance.
In case of rs104893911 the resistance is accompanied
by the hypokalemia and pseudohermaphroditism [30].
The main symptom of the glucocorticoid resistance is
the high level of cortisone and ACTH in the blood
plasma which may be related to the increase in the
concentration of mineral-corticoid hormones and sex
steroids [30].
The majority of the missence polymorphisms,
studied in the human population, are remarkable for
rather low frequency of incidence; there are rare
homozygotes of mutant alleles, which may be ex-
plained by their inviability (see Table 5). In its turn, the
low frequency of heterozygotes indicates a conside-
rable effect of the negative natural selection regarding
the mutations of NR3C1 gene [31] which may be
related to its significant role in the stress conditions and
adaptation processes.
Polymorphisms of non-coding sites of the gene
and other forms of non-missence mutations. The
majority of SNPs in humans belong to intron sequences
of the gene, which are adjoining the exons [31]. There
are also some known mutations in the alternative exons,
coding for the GR receptor isoform and the mutations,
adding some more amino acids to the existing exons.
The general description of these SNPs is presented in
Table 6.
Among all the polymorphisms, listed in Table 6,
noteworthy are two polymorphisms of the highest
clinical relevance: rs6198 and rs41423247.
The polymorphism rs6198 is the replacement of
nucleotide A by G in position 3669 (exon 9) [31]. The
mutant variant leads to the change in the stability of
variant GR- mRNA, and thus to its intensified
synthesis. This GR isoform plays the role of dominant
inhibitor of the active alpha-form of the receptor,
inducing the reduced response to glucocorticoids.
Therefore, the mutant form of the gene exhibits in a
lower basal level of arterial pressure [31] as well as in
an increased risk of rheumatoid arthritis and systemic
lupus erythematosus [32] which might be explained by
enhanced anti-inflammatory response, caused by the
decreased sensitivity to glucocorticoids [31]. In ad-
dition, the formation of SNP by rs10482605 is faci-
litated by the haplotype, related to the increased risk of
developing the major depression [5]. In total, the fre-
quency of the mutant form in the Caucasian population
of the USA is 19 %. SNP is remarkable for its dominant
character which allows considering heterozygotes as a
risk group for the described diseases.
Another widespread polymorphism rs41423247,
also called Bc1I, is related to the replacement of C by G
in position 41503, corresponding to the intron region of
the gene [33]. It suggests the involvement of the
mutation into the mechanisms of alternative splicing of
mRNA and the changed products of receptor isoforms.
The incidence degree for the minor allele is 26.4 %
which defines this polymorphism as one of the most
widespread variants of NR3C1 gene in the human
population. SNP causes enhanced sensitivity to gluco-
corticoid hormones [33]. Many studies revealed that the
carriers of Bc1I have increased risk of recurrent mis-
carriage [34], bronchial asthma [35], juvenile idiopa-
thic arthritis [36] which may be caused by the decreased
level of corticosterone, observed due to the enhanced
sensitivity of GR receptors and the activated negative
feedback loop of the regulation of HPA activity [37].
Other forms of polymorphisms with clinical
description. Among all the known polymorphisms of
NR3C1 gene a special place is reserved to the mu-
tations, revealed either very rarely or in families and
remarkable for their vivid clinical picture. These
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Fig. 4 Regional density of
SNPs in various sites of
NR3C1 gene
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dbSNP ID Replacement
Position in
GR- protein
Protein
domain
Frequencies
(wild/hetero/mutant)
Clinical state Mechanism
1 2 3 4 5 6 7
rs61759024 Pro  Ser 9 TAD 99,9/0,1/0; N = 4428 n/d Close of Tre8 phosphorylation
site
rs6190
ER22/23EK
Arg  Lys 23 TAD 90,3/9,7/0; N = 226
(åâðîï.)
Associated with glucocorticoid resistance at Kron’s
disease [44]; one work demonstrates the association of
cortisone products at social stress [45], while another
one does not [46]
rs72481829 Asp  Asn 25 TAD 0,6/0/99,4; N = 356 n/d n/d
rs148102613 Phe  Leu 29 TAD 100/0/0; N = 4550 n/d n/d
rs143711342 Tyr  His 30 TAD 99,0/0,1/0; N = 4550 n/d n/d
rs148967394 Ser  Pro 44 TAD 100/0/0; N = 4550 n/d
Adjoins Ser45 phosphorylation
site, which may result in the
decrease in transactivational
ability of receptors
rs79138720 Val  Gly 50 TAD
Non-clinical source
n/d n/d
rs6192 Phe  Val 65 TAD 99,2/0,8/0; N = 4450
No effect of the basal level of arterial pressure [31]
rs145020010 Met  Val 98 TAD 100/0/0; N = 4222 n/d n/d
rs72542740 Gly  Arg 99 TAD 99,8/0,2/0; N = 526 n/d n/d
rs72481830 Asn  Ser 130 TAD 99,4/0,6; N = 360 n/d n/d
rs141093427 Phe  Leu 156 TAD 100/0/0; N = 4548 n/d n/d
rs186831584 Val  Ile 163 TAD n/o n/d n/d
rs146524172 Asn  Ser 180 TAD 100/0/0; N = 4550 n/d n/d
rs140309412 Asn  Ile 222 TAD 100/0/0; N = 4224 n/d n/d
rs72542742 Ala  Thr 229 TAD 99,7/0,3/0; N = 4132 n/d n/d
rs183372229 Leu  Phe 286 TAD n/o n/d n/d
rs72542743 Ile  Val 292 TAD Alleles: 99,8/0,2;
N = 526
Close to Lys419 sumoylation site
rs72542745 Ser  Gly 325 TAD Alleles: 99,8/0,2;
N = 526
n/d n/d
rs72558022 Asp  His 346 TAD 94,4/5,6/0; N = 18 n/d n/d
rs148470701 Gln  Glu 347 TAD n/o n/d n/d
rs6195N363S Asn  Ser 363 TAD 95,8/4,2/0; N = 48
rs56149945 Asn  Ser
Asn  Ile
363 TAD 95,9/4,0/0/0; N =
4550
Known clinical case
rs1800445 Asn  Ser 365 TAD n/o n/d n/d
Table5
Missens SNPs
mutations promote deeper understanding of the functi-
onal relevance of the receptor and the mechanisms of
controlling its activity. Below is a short description of
two mutations, described in scientific literature.
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1 2 3 4 5 6 7
rs147136661 Ser  Phe 370 TAD 100/0/0; N = 4544 n/d n/d
rs145046100 Thr  Ala 413 TAD n/o n/d n/d
rs113048309 Ser  Pro 425 DBD n/o n/d n/d
rs104893913 Arg  His 477 DBD n/o n/d n/d
rs72542747 Thr  Ser 504 HD n/o n/d n/d
rs72481843 Gly  Ala 516 HD Single case n/d n/d
rs33391 Asn  Lys 517 HD Eight cases, not
observed in the
population
rs104893911 Val  Ala 571 LBD ? Possible pathogenecity
rs104893909 Ile  Asn 559 LBD Single case n/d n/d
rs104893908 Asp  Val 641 LBD Single case PGR Reduced affinity to the
hormone, impaired
transportation into the nucleus,
receptor instability [39]
rs113100205 Val  Ile 658 LBD Îäíà ñåìüÿ n/d n/d
rs104893914 Gly  Ser 679 LBD n/o PGR
Reduced transactivational effect
[47]
rs68012717 Asp  Glu 687 LBD n/o
rs121909727 Phe  Leu 737 LBD Single case TGR Reduced affinity to the
hormone, delay in nuclear
translocation and impaired
interaction with NCOA2
(GR-interacting protein-1
co-activator) [48]
rs104893910 Ile  Met 747 LBD ?
rs121909726 Leu  Phe 753 LBD n/o
rs186936077 Asn  Asp 766 LBD n/o
rs104893912 Leu  Pro 773 LBD Single case TGR Two-fold reduction in
transactivational ability,
dominant-negative effect on
wild type of the receptor,
slowed-down translocation into
the nucleus, impaired
interaction with NCOA2 [49]
Note. DBD – DNA-binding domain; LBD – ligand-binding domain; TAD – transactivational domain; HD – hinged domain; PGR and TGR
– primary and total glucocorticoid resistance; n/o – no observation; n/d — no data.
Îêîí÷àíèå òàáë. 5
In 1976 the authors of [38] described a medical
case, when a patient had a high level of cortisone and
ACTH associated with hypertension and hypokalemia
with no other deviations. The proband’s DNA demon-
strated the mutation of SNP type, consisting in the
substitution of valine for asparagine in position 641 of
GR-, corresponding to the hormone-binding domain
(rs104893908) [39]. The mutation induced the decrease
in the affinity to cortisone, the impaired transportation
of the receptor into the nucleus and its total instability
[39].
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dbSNP ID TypeSNP Minor allele frequency Mutation region clinical significance
rs7701443 A/G G: 46,8 %; N = 1022 Intron Resistance to corticosteroids in children with Crohn's disease
[44]
rs9324924 G/T T: 44,8 %; N = 978 Intron Data on the relationship with glucocorticoid resistance have not
been identified [50]
rs4912911 A/G G: 44,8 %; N = 1000 Intron Recessive resistance to corticosteroids [44]
rs4607376 A/G G: 43,8 %; N = 957 Intron Data on the relationship with glucocorticoid resistance have not
been identified [50]
rs6191 G/T G: 42,3 %; N = 923 Exon 9/3'-flanking
region
Possible relation with lithium resistance in patients with bipolar
disorder [51] due to depression [51]
rs33388 A/T A: 41,6 %; N = 908 Intron Possible relation with lithium resistance in patients with bipolar
disorder [51] due to depression [51], there is no association with
rheumatoid arthritis [51] is not shown due to depression in
women in pre-menopausal women [52]
rs6198 A/G G: 9,2 %; N = 201 Exon 9/3'-flanking
region
See description in text
rs41423247 C/G C: 27,7 %; N = 604 Intron See description in text
rs6196 A/G G: 13,8 %; N = 302 Additional Asn in
exon 5
Resistance to corticosteroids in children with Crohn's disease
[44], communication with overweight [54], there is no
inter-connection with the response to psychosocial stress in
children, the association to high blood pressure [31]
Table 6
The main clinically significant SNP in noncoding regions of the NR3C1gene
1A 1B 1C 2 3 4 5 6 7 8 9 9
1
9
8
2
10 11 12 13 14 15
7
6
5
3
4
*
*
Fig. 5 The scheme of SNPs in the composition of the main haplotypes of NR3C1 gene (according to [31]). Detailed description of SNP and
haplotypes is presented in Table 7.
Noteworthy are three medical cases, revealed by the
authors of [29] in one Danish family, caused by the
deletion of four nucleotides in the donor splice site
(here the pairs of nucleotides belonged to the sites of
sixth intron and exon). The carriers of the clinical
pathology were the father and three of five children; all
these patients had evident hypercortisolism, caused by
the functioning of only half of GR receptors. The
proband was the daughter with hyperandrogenism,
caused by the compensatory hyperproduction of the
corticosteroid hormones [29].
Haplotypes of NR3C1 gene in humans. The work
[31] presents the detailed study of the NR3C1 gene
haplotypes, consisting of various combinations of sepa-
rate SNP, widespread among the main ethnic groups of
American population. There were eight main revealed
haplotypes, consisting of two and more SNP, which
occur in the associations at the values of correlation
coefficient 0.8 and over (Fig. 5, Table 7). In addition,
the authors distinguished seven additional haplotypes,
containing only one SNP, which are either rather
frequent among Americans or of considerable rele-
vance. It was established that haplotypes No. 2 and 3
are notable for their statistically reliable relation to the
increased levels of the arterial pressure [31].
Unfortunately, at present we are unsuccessful in
finding other studies on the NR3C1 gene haplotypes
with sufficient representation.
Conclusions. Modern medical science is moving
towards combining the results of genetic and molecular
biological investigations with the clinical practice. The
focus of the scientists tends to shift from the study on
the monogenic diseases of low incidence level, but
with a vivid and specific clinical picture, to the analysis
of molecular mechanisms of polygenic, multifactorial
diseases, which are widespread and remarkable for
many clinical variants and types of the clinical course.
In this regard there is a special interest to the gluco-
corticoid hormone receptors, which are one of the key
regulators of immunological, stress and adaptation
processes. The study on the relation of molecular
biology and genetics of the GR receptors to the
development of various forms of clinical pathological
states and diseases offers new opportunities for further
research in the sphere of pathophysiology and therapy
of the diseases of civilization.
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haplotype SNP ID SNP region
1 –1225 Distal promoter
rs6868190 Distal promoter
2 rs10482616 Intron 1C
rs10482672 Intron 3
3 rs852978 Intron 3
rs6196 Exon 9 (additional Asn)
rs258748 3'-flanking region
4 rs852979 Intron 3
rs6188 Intron 4
rs258813 Intron 7
rs258750 Intron 8
5 rs6191 Exon 9/3'-flanking region
rs258747 3'-flanking region
6 rs10482605 Proximal promoter
rs10482605 Intron 2
rs123324 Intron 3
rs10482689 Intron 6
rs6198
Exon 9/3'-flanking regionü
(AUUUA-sequence)
rs17287758 3'-flanking region
7 rs4986593 Intron 2
rs17209237 Flanking region
8 rs10482604 Proximal promoter
rs6192 Exon 2 (Phe  Val)
rs10043662 Exon 9/3'-flanking region
9 –921 Distal promoter
10 rs6195 Exon 2 (Asn  Ser)
11 rs41423247 Intron 2 (BclI)
12 rs10482669 Intron 3
13 rs10482682 Intron 5
14 rs258751 Exon 8 (additional Asp)
15 rs6193 Exon 9/3'-flanking region
Table7
Description of the main gene NR3C1 haplotypes , in the African
Americans, Mexican and European Americans population ([31])
Ì. À. Îðëîâñêèé
Àëëåëüíûé ïîëèìîðôèçì ðåöåïòîðà ãëþêîêîðòèêîèäíûõ ãîðìî-
íîâ NR3C1 (GR):
îò ìîëåêóëÿðíîé áèîëîãèè ê êëèíèêå
Èíñòèòóò ôèçèîëîãèè èì. À. À. Áîãîìîëüöà ÍÀÍ Óêðàèíû
Óë. Àêàäåìèêà Áîãîìîëüöà, 4, Êèåâ, Óêðàèíà, 01024
Ðåçþìå
Ïîëèìîðôèçì ãåíîâ, ó÷àñòâóþùèõ â ðåàëèçàöèè ñòðåññîðíîãî
îòâåòà, ÿâëÿåòñÿ îäíèì èç êëþ÷åâûõ ôàê- òîðîâ, îïðåäåëÿþùèõ
ðàçëè÷èÿ â ñòðåññ-ðåàêòèâíîñòè è ðåçèñòåíòíîñòè â ÷åëîâå÷åñ-
êîé ïîïóëÿöèè. Ñðåäè ãåíîâ – ðåãóëÿòîðîâ ñòðåññà â ïåðâóþ î÷å-
ðåäü ñëåäóåò âûäåëèòü ãåíû ðåöåïòîðîâ ãëþêîêîðòèêîèäîâ. Â
îáçîðå äàíà äåòàëüíàÿ õàðàêòåðèñòèêà èõ ìîëåêóëÿðíîé áèîëî-
ãèè, íà îñíîâàíèè ÷åãî ïðîâåäåí àíàëèç âîçìîæíîé ñâÿçè íàèáîëåå
ðàñïðîñòðàíåííûõ âàðèàíòîâ SNP ñ àëüòåðàöèåé ñòðåññîðíûõ
ðåàêöèé è ðàçâèòèåì êëèíè÷åñêîé ïàòîëîãèè.
Êëþ÷åâûå ñëîâà: ãëþêîêîðòèêîèäíûå ðåöåïòîðû, àëëåëüíûé
ïîëèìîðôèçì, SNP, NR3C1, GR, áîëåçíè àäàïòàöèè.
Ì. Î. Îðëîâñüêèé
Àëåëüíèé ïîë³ìîðô³çì ðåöåïòîðà ãëþêîêîðòèêî¿äíèõ ãîðìîí³â
NR3C1 (GR): â³ä ìîëåêóëÿðíî¿ á³îëîã³¿ äî êë³í³êè
Ðåçþìå
Ïîë³ìîðô³çì ãåí³â, ÿê³ áåðóòü ó÷àñòü ó ðåàë³çàö³¿ ñòðåñîðíî¿ â³ä-
ïîâ³ä³, º îäíèì ³ç êëþ÷îâèõ ôàêòîð³â, ùî âèçíà÷àþòü ðîçá³æíî-
ñò³ â ñòðåñ-ðåàêòèâíîñò³ ³ ðåçèñòåíòíîñò³ â ëþäñüê³é ïîïóëÿö³¿.
Ñåðåä ãåí³â – ðåãóëÿòîð³â ñòðåñó ó ïåðøó ÷åðãó âàðòî â³äçíà÷èòè
ãåíè ðåöåïòîð³â ãëþêîêîðòèêî¿ä³â. Â îãëÿä³ íàäàíî äåòàëüíó õà-
ðàêòåðèñòèêó ìîëåêóëÿðíî¿ á³îëîã³¿ äàíèõ ãåí³â, íà ï³äñòàâ³ ÷îãî
çðîáëåíî àíàë³ç ìîæëèâîãî çâ’ÿçêó íàéðîçïîâñþäæåí³øèõ âàð³àí-
ò³â SNP ç àëüòåðàö³ºþ ñòðåñîðíèõ ðåàêö³é òà ðîçâèòêîì êë³í³÷-
íî¿ ïàòîëîã³¿.
Êëþ÷îâ³ ñëîâà: ãëþêîêîðòèêî¿äí³ ðåöåïòîðè, àëåëüíèé ïîë³-
ìîðô³çì, SNP, NR3C1, GR, çàõâîðþâàííÿ àäàïòàö³¿.
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